Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More
Summary
—Albireo Pharma (NASDAQ: ALBO) reported preliminary data showing that its experimental drug, odevixibat, met the main goals of a Phase 3 study in progressive familiar intrahepatic cholestasis, a rare inherited liver disorder. —Intra-Cellular Therapies (NASDAQ: ITCI) drug lumateperone met the main goals of a study in bipolar depression and the New York biotech plans an FDA submission late this year or in early 2021. —Wu Capital led a $91.5 million Series A financing for Korro Bio, a Cambridge-based biotech developing technology that aims to treat disease by harnessing the body’s natural base-editing system to make single base edits to RNA. —Pfizer pumped $25 million into Trillium Therapeutics (NASDAQ: TRIL), an investment that follows the biotech’s report of encouraging early dose-escalation data for two experimental therapies designed to target the cancer protein CD47. —Grail, developer of blood cancer tests intended to detect early signs of the disease before symptoms are apparent, filed to go public as it prepares to commercialize its liquid biopsy technology next year.
Funding
Review available funding amount, funding date, investors, and linked company information related to Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
